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ABSTRACT 
A series of public health disasters (Thalidomide in the 1960s to Rofecoxib (Vioxx) at the beginning of this century have served to remind us that 
effective Pharmacovigilance (PV) is crucial for protection of citizens. The introduction of new PV legislation in July 2012 is the biggest change to the 
regulation of human medicines in the European Union (EU) since 1995. New requirements and procedures for Post-Authorization Safety Studies 
(PASS) open the gateway for development of real-world effectiveness outcomes. Similarly, the United States Food and Drug Administration (USFDA) 
has become more open to inclusion of non-safety data collection in its safety surveillance mandates and more proactive risk management approach. 
In addition, the Marketing Authorisation Holders (MAHs) need to be more efficient with their post-authorisation activities to maximize their utility. 
The main goal of this new PV path is to strengthen the public health. However it is also concerned with improved efficiency, clear decision-making 
processes, reduce duplication and better use of Information Technology in PV process. 
Keywords: Pharmacovigilance, European Medicine Agency, Good Pharmacovigilance practice, New EU PV Legislation, Food and Drug 
Administration, Signal detection, Risk Management Plan. 
 
INTRODUCTION 
In accordance with data of European Commission (EC), adverse drug 
reaction (ADRs) are responsible for 5% of all hospital admissions, 
5% of all patients in hospital experience an ADR and lastly ADRs 
cause minimum of 1.91 extra days of hospitalization. In United 
States (US), more than 100,000 deaths annually are because of ADRs [2]. 
Hence, this scenario itself makes clear the importance of 
pharmacovigilance (PV), as “the science and activities relating to the 
detection, assessment, understanding and prevention of adverse effects 
or other drug related problems” [3]. PV is crucial in all phases of drug 
development process and is based on effective systems and processes 
that are dependent on regulations in various countries and regions. 
New eu pv legislation 
On December 10, 2008, EC published proposals to amend European 
Union (EU) PV legislation contained in the Directive 2001/83/EC 
and Regulation 726/2004/EC. In July 2012, new legislation with 
Directive 2010/84/EU and Regulation 1235/2010 substantially 
amended the EUs PV requirements by strengthening and 
consolidating the PV system [4, 5]. The legislation is the biggest 
change to the regulation of human medicines in the EU since 1995. 
The EU PV system is now one of the most advanced and 
comprehensive systems in the world and represents a robust and 
transparent instrument to ensure a high level of public health 
protection. 
New definition of adverse drug reaction: 
An adverse drug reaction is a response to a medicinal product which 
is noxious and unintended. This includes adverse reactions which 
arise from:  
• The use of a medicinal product within the terms of the marketing 
authorisation. 
• The use outside the terms of the marketing authorisation, 
including overdose, off-label use, misuse, abuse, medication errors 
and occupational exposure [6]. 
Need for new eu pv legislation 
As ADRs are the fifth most common cause of hospital death and they 
are accountable for EU societal cost of £79 billion per year [7], hence 
a change was required in the existing legislation to protect public 
health. This would have been possible with a high level objective 
with clear roles and responsibilities; risk based/proportionate 
approach; increased proactiveness and proper planning resulting in 
integrated benefit and risk of products. With the recent changes, the 
EU intends to promote and protect public health by reducing burden 
of ADRs and optimizing the use of medicines. 
What about volume 9a?  
The key to the success of the legislation is the Good 
Pharmacovigilance Practice (GVP) document which replaced Volume 
9A. The Figure 1 shows various GVP Modules and these were made 
modular to enable easier amendments. All key modules were 
available by July 2012 [8]. 
Main pillars of new pv legislation 
Reduction in administration burden/increased work-sharing  
This new legislation clearly states the roles and responsibilities of 
European Medicines Agency (EMA), member states and the 
Marketing Authorization Holders (MAHs). The EMA and member 
states remain central to the operation of the PV with increased co-
operation and work sharing. The role of the MAH is more clarified in 
reference to obligation to monitor the safety of the products and to 
ensure that all information available is shared with Competent 
Authorities (CAs) [9]. 
Greater transparency - medicines web-portals (EU & national) 
and products subject to ‘additional monitoring’  
The regulatory agencies and member states have the substantial 
powers to make following information of medicinal products from 
MAHs available on web portal and in public domain [10]: 
– Summaries of Periodic Safety Update Reports (PSURs) and Risk 
Management Plans (RMPs) with issues. 
– Information pertaining to Public Assessment Reports (PARs), 
Summary of Product Characteristics (SmPCs) and Patient 
Information Leaflets (PILs). 
– Publicly available list of medicinal products subjected to 
additional monitoring. It includes identification of these products by 
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black symbol, a PRAC recommendation to EC and explanatory note 
in SmPCs and PILs.Online ADR reporting forms and information 
pertaining to various ways of reporting ADRs by Health Care 
Professionals (HCPs) and Patients. The MAHs and MSs are supposed 
to report serious ADRs within 15 days and non-serious ADRs within 




















































Fig. 1: GVP Modules 
 
Pharmacovigilance Risk Assessment Committee (PRAC)  
8 
The creation of PRAC has an important role in all aspects of Risk 
Management (as shown in Figure 2) of the use of medicinal 
products. This includes detection, assessment, minimisation and 
communication relating to the risk of adverse reactions, due regard 
to the therapeutic effect of the medicinal product, the 
design/evaluation of the PASS and PV audit.  For specific activities of 
signal management, the PRAC appoints a rapporteur from amongst 
its members. The role of the PRAC rapporteur is to prepare a 
recommendation or an advice together with an assessment report 
on the relevant issue pertaining to signal detection that is raised to 
PRAC, taking into account the timeframe laid down in the relevant 
legislation. The PRAC rapporteur also provides recommendations to 
Committee for Medicinal Products for Human Use (CHMP) or the 
Coordination Group for Mutual Recognition and Decentralized 
Procedures - Human (CMDh) lead Member State/Reference member 
state for the concerned medicinal product [11]. 
 
Risk Minimization
Risk Detection/ Signal 
Detection





Fig. 2: Role of PRAC in Risk Management 
 
12 
In relation to specific activities of the PRAC, rapporteur contacts 
with representatives of patient organizations’ and relevant health-
care professionals' associations and rapporteur provides a report on 
the outcome of such contacts to the PRAC, which is reflected in 
assessment report.  
The PRAC also plays a crucial part in handling of direct ADR reporting 
by consumers irrespective of medical confirmation. Lastly, PRAC has a 
big role in monitoring of RMPs and assessment of list of harmonised 
frequencies pertaining to submission of PSURs/PBRERs [12]. 
PV system Master File (PSMF) 
As per the new legislation, Detailed Description of 
Pharmacovigilance System (DDPS) will no longer be required and is 
replaced by PSMF. On request, the PSMF should be provided within 
seven days to CAs. The annexes of the PSMF contain comprehensive data 
demonstrating the current state of the PV system, including [13]: 
– An overview of all marketing authorisations covered by the PSMF 
together with information on presence on the market (also outside 
EU) and specific safety monitoring requirements 
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– Results of the current performance assessment [e.g. timeliness of 
Individual Case Safety Reports (ICSRs) reporting and PSUR 
submission, safety variations and adherence to RMP requirements] 
– An audit schedule and critical findings from previous PV audits 
– A detailed overview on the company’s written procedures 
Risk Management Plans (RMPs) 
RMP is defined as, "a set of PV activities and interventions designed 
to identify, characterize, prevent or minimize risks related to a 
medicinal product, including the assessment of effectiveness of 
those activities and interventions". In accordance to new legislation, 
RMP should be risk proportionate and needs to be submitted for all 
new products. The authorized products require RMP if there are 
issues affecting the risk benefit balance. The new legal requirement 
states that "EMA and MS's shall monitor the outcome of risk 
minimisation measures contained in the RMPs." [14]. 
Signal Detection 
The GVP clearly sets out the concept of signal detection, validation, 
prioritization, evaluation and communication. The MAHs needs to 
have documented processes for signal detection in accordance with 
the level of reports received and portfolio of medicinal products. It 
may include individual case review, statistical analysis or a 
combination of both [15]. 
Periodic Safety Update Reports (Addendum to Clinical Reports 
and PSURs) 
The concept of Addendum to the Clinical Overview reports has been 
expanded and these reports should include a benefit/risk evaluation 
in renewal applications. The PSURs will not be required for generic 
and traditional herbal medicinal products. However, CAs can request 
PSURs for these products on the basis of various safety concerns. In 
addition, PSUR is replaced with Periodic Benefit Risk Evaluation 
Report (PBRER) and MAHs shall submit PBRERs/PSURs containing 
summaries of data relevant to benefits and risks of the product. The 
new features of the PBRER are [16]: 
– Focus on benefit and risk 
– Emphasis on analysis and evaluation, in reference to active 
substance 
– Focus on cumulative data, with no case line listings (no individual 
case line listings, no tables of listed vs. unlisted) 
– The submission frequency is determined by drug’s risk profile 
Pharmacovigilance in united states 
The Center for Drug Evaluation and Research (CDER) and the Center 
for Biologics Evaluation and Research (CBER) of the USFDA monitor 
and review safety information throughout life cycle of the medicinal 
product, from application for MA through approval of the 
application and after entry of drug in the market. The Food and Drug 
Administration Amendments Act (FDAAA), has a pivotal role in 
safety of drugs during post-marketing phase. It provides FDA with 
the authority to require labeling changes with respect to new safety 
information. The FDAAA also gives FDA the authority to require 
certain post-marketing studies and clinical trials for new drugs 
approved under Food, Drug and Cosmetic Act (FDCA) or for 
biological medicinal products. 
The routine PV activities in US i.e. compliance with applicable post-
market requirements under the FDCA and USFDA implementing 
regulations includes post-marketing surveillance and risk 
assessment. The PV plan describes efforts beyond the routine post-
marketing spontaneous reporting and is designed to enhance and 
expedite the sponsor’s acquisition of safety information. The 
sponsors have to develop a PV plan for products for which; serious 
safety risks have been identified post-approval and/or already 
identified safety risks need more evaluation or risk populations have 
not been adequately studied. Under USFDA, guidance to cover the 
different phases of the risk assessment and risk management for 
industry is divided into three parts [17]: 
Premarketing risk assessment 
The MAH is responsible for reviewing all information pertaining to 
safety of the drug obtained or otherwise received by the MAH from 
any sources or from any clinical or epidemiological investigation. 
The MAH needs to notify USFDA and all participating investigators 
in Investigational New Drug (IND) safety report of all serious and 
unexpected serious risk from clinical trials or any other sources that 
has not previously been reported to the Agency [17]. 
Post-marketing Pharmacovigilance and Pharmaco 
epidemiologic Assessments 
The PV in US encompasses all scientific and data gathering activities 
relating to the detection, assessment, and evaluation of safety signals 
[17]:  
– Safety signal identification  
– Pharmacoepidemiologic assessment and safety signal 
interpretation  
– Pharmacovigilance plan development  
Risk Evaluation and Mitigation Strategies (REMS)  
The USFDA has obligation for manufacturers to implement special 
risk management programs, called REMS. The Secretary, in 
consultation with the office responsible for reviewing the drug and 
the office responsible for post-approval safety of the drug, 
determines the requirement of REMS. If the benefits of drug 
outweigh the risks, then the applicant having an approved 
application for new drug or abbreviated new drug or biological 
medicinal product has to submit REMS. The proposed REMS must be 
submitted within 120 days of the USFDA notification for the 
protection of public health [18]. The risk assessment and risk 
minimization together is called as Risk Management and it is an 
iterative process throughout a product’s lifecycle which consists of 
[18, 19]: 
– Assessing a product’s benefit-risk balance;  
– Developing and implementing tools to minimize its risks while 
preserving its benefits;  
– Evaluating tool effectiveness and reassessing the benefit-risk 
balance;  
– Making adjustments, as appropriate, to the risk minimization 
tools to further improve the benefit-risk balance [19].  
In US, under Title 21 of Code of Federal Regulation (CFR) §§ 314.80, 
314.98, 600.80, Periodic adverse drug experience reports (PADERs) 
shall contain among other data, information about all serious 
expected and non-serious adverse events, which are not reported 
through the post-marketing “15-day Alert reports” or their follow-
up reports. These periodic reports also include a narrative summary 
of information in the report and an analysis of “15-day Alert reports” 
submitted during the reporting intervals [20]. 
  
 
Fig. 3: National Pharmacovigilance Program (NPP) of India 21 
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Pharmacovigilance in india 
The Legislative requirements of PV in India are guided by 
specifications of Schedule Y of the Drugs and Cosmetics Act 1945. 
The National Pharmacovigilance Programme (NPP) shown in Figure 
3 was launched by Central Drugs Standard Control Organization 
(CDSCO) on 23-Nov-2004 which became operational from 01-Jan-
2005. However, due to some technical difficulties the NPP was 
closed in 2008. It was again resurrected as the Pharmacovigilance 
Programme of India (PVPI) on 14-Jul-2010 [21]. 
In order to ensure implementation of the programme in a more 
effective way the National Co-ordination centre (NCC) at AIIMS, New 
Delhi was shifted to CDSCO in collaboration with Indian 
Pharmacopoeia commission, Ghaziabad on 15-Apr- 2011 [21]. The 
Figure 4 shows elements of PVPI. To streamline the growth of the 
PVPI programme further, the commission has planned to include all 
medical colleges across the country under its fold. The commission 
aims to expand PVPI and attain its goal of setting up 350 ADR 















Promotion of ADR reporting
Collection and evaluation of ADR reports
Post-marketing surveillance of drugs
Monitor benefir-risk profile of drugs 
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 (PVPI) 
The role of various Regulatory agencies in India [23] is summarized in Table 1 below: 
 
Table 1: Roles of various regulatory agencies of India 
Agencies Role of agencies 
Drug Controller General of India 
(DCGI)  
Implementation the NPP in India 
Central Drugs Standard Control 
Organization (CDSCO)  
Operate under the supervision of National Pharmacovigilance Advisory Committee to recommend 
procedures and guidelines for regulatory interventions.  
Indian Council of Medical Research 
(ICMR)  
Brought out the 'Policy Statement on Ethical Considerations involved in Research on Human Subjects' in 
1980 and revised these guidelines in 2000 as the 'Ethical guidelines for Biomedical Research on Human 
Subjects'.  
Ministry of Health and Family 
Welfare (MHFW)  
An autonomous body for setting of standards for drugs, pharmaceuticals and healthcare devices and 
technologies in India. 
National Pharmacovigilance 
Advisory Committee (NPAC)  
To collate, analyze and archive adverse drug reaction data for creating healthy environment for the 
regulatory authorities to analyze drugs to be marketed in India  
Central Bureau of Narcotics (CBN)  
 
Closely monitor all clinical trials, which require additional narcotics compliances relating to storage, import-
export quotas and movement of the investigational drug.  
Department of Biotechnology (DBT)  Provides product evaluation and validation through support for field trials for agriculture products and 
clinical trials for health care products.  
 
Pharmacovigilance concepts in eu, us and india  
In both EU and US, PV activities cover the whole life-cycle of 
medicinal products for human use.  
The full safety profile of medicinal products can only be known after 
marketing of the products and in this period, pharmacovigilance 
activities become especially important for the protection of public 
health.  
The EMA and the National CAs in EU and USFDA are empowered to 
impose certain obligations on authorized medicinal products with 
respect to new safety information, to ensure appropriate changes to 
medicinal product’s labeling and to conduct post-authorization 
safety studies.  
The PV system in both areas demand expedited and obligational 
recording and reporting of all available data about the serious 
unexpected adverse events, medication errors and any suspected 
transmission of an infectious agent through the medicinal products.  
The PV is still in its infancy in India and is likely to expand in accordance 
with time. The entry of new drugs in market demands more PV activities.  
The PV concepts in EU, US and India [4, 5, 11-21, 23] are 
summarized in Table 2 below: 
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Table 2: Comparison of PV in EU, US and India 
Topics EU US INDIA 
Regulatory 
Structure 




Regulation 1235/2010 and Directive 
2010/84/EU  
21 CFR §§ 314.80,314.98, 600.80 
 




PSMF is required and it is aimed to 
strengthen and rationalize the 
monitoring of safety information of 
medicinal products in EU market and to 
harmonize the PV activities throughout 
EU. 
 
In accordance with CFR, which demand 
from the applicants having approved new 
drug applications (NDAs) or approved 
abbreviated new drug applications 
(ANDAs) and from manufacturer having 
licensed biologic applications to archive 
and retain records of all adverse events, 
known to them, including raw data and 
any correspondence relating to adverse 
drug experience. 
The CDSCO in collaboration with Dept 
of Pharmacology, AIIMS, New Delhi 
launched the nation-wide 
Pharmacovigilance programme for 
protecting the health of patients by 
assuring drug safety. The programme is 
coordinated by Department of 
Pharmacology at AIIMS as a NCC. The 
centre operates under the supervision 
of a Steering Committee. 
Electronic 
Databases 
Permanently accessible electronic 
database (the Eudravigilance Database) 
for collection, collation and 
dissemination of information on 
suspected adverse reactions to 
medicinal products for human use 
authorized by the Union. The 
Eudravigilance database is equipped to 
immediately forward reports on 
suspected adverse reactions received 
from MAHs to the MS, on whose 
territory the reaction occurred. 
FDA’s Adverse Event Reporting System 
(FAERS) and FDA’s Vaccine Adverse 
Event Reporting System (VAERS) are 
computerized information databases 
designed to support FDA’s post-
marketing safety surveillance program 
for drugs/biological products and for 
vaccines, respectively. 
Vigiflow software provided by WHO-
Uppsala Monitoring Centre is utilized 
as the safety database, where all data 
originating from India is maintained in 
a secure and confidential manner. 
PV Plan 
 
In Europe, ICH E2E guideline on PV 
Planning suggests that a “PV plan” 
would routinely be developed, even 
when the sponsor does not anticipate 
that enhanced PV efforts are necessary. 
In US, for most products routine PV 
activities (i.e. compliance with applicable 
post-market requirements under the 
FDCA and FDA implementing 
regulations) will be sufficient for post-
marketing surveillance and risk 
assessment, and a PV plan describes PV 
efforts beyond the routine post-
marketing spontaneous reporting, and is 
designed to enhance and expedite the 
sponsor’s acquisition of safety 
information. 
The PVPI NCC is collaborated with the 





The medicinal products for pediatric 
use and those involving a significant 
change in the MA, including a new 
manufacturing process have to 
implement a risk management system 
and all new marketing authorization 
application (MAA) have to contain a 
RMP with a detailed description of the 
risk management system used by MAH. 
The applicant having an approved 
application for new drug or for 
abbreviated new drug or for a biological 
medicinal product has to submit REMS. If 
FDA believes that REMS is necessary to 
assure that the drug’s benefits outweigh 
its risk, the manufacturers have to 
implement REMS for the drug. 
 
No Specific Guideline 
Spontaneous 
Case reports 
To be reported by MAH within 15 
Calendar days 
Serious and unexpected, foreign and 
domestic are to be reported by MAH 
within 15 calendar days  







To be reported by MAH within 15 
Calendar days 
Serious and unexpected, foreign and 
domestic are to be reported by MAH 
within 15 calendar days 
 










All serious adverse reactions 
within or outside the EU should be 
reported within 15 days. 
Serious and unexpected adverse 
experiences (domestic and foreign) 
should be reported within 15 calendar 
days 
No Specific Guideline 




As soon as possible but no later than 7 calendar days after first knowledge followed by a complete report as possible within 8 










The PBRER does not work anymore as 
a detailed listing of ICSRs. The 
The PADERs shall contain among 
information about all serious expected 
The PSURs are submitted every 6 
monthly for the first 2 years of 
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submission of periodic reports is also 
exempted for MAHs of generic, well-
established used, homeopathic or 
traditional-use herbal medicinal 
products. Frequency of submission is 6-
monthly continued until two full years 
then, once a year for the following 2 
years and thereafter at 3- yearly 
intervals. 
and non-serious adverse events, not 
reported through the post-marketing 
“15-day Alert reports” or their follow-up 
reports. A narrative summary of the 
information in the report and an analysis 
of the “15-day Alert reports” is also 
included in these reports. The periodic 
reports are submitted quarterly for first 
three years, then annually. 
marketing in India, and annually for the 
subsequent 2 years. 
In addition, both REMS and RMPs provide positive guidance for identification, monitoring, and minimization of risk to patient safety. A summary of 
elements [24] of RMPs and REMs are described in Table 3 below: 
 
Table 3: EMA-RMP and USFDA-REMS 
EMA-RMPs USFDA-REMS 
Patient alert cards Medication guides 
Patient information leaflet Patient information sheet 
SmPC contraindications 
SmPC special warnings and precautions for use 
Container labels 
SmPC contraindications Provider communication plan 
Provider information sheet 
Educational programmes Highlighted information for prescribers 
Training of healthcare professionals 
Prospective observational studies Monitoring of patients receiving medication 
Additional trial and study data Prescriber and patient database 
Specific adverse event and pharmacovigilance surveillance reporting requirements  Post marketing studies 
 
Challenges for new eu pv legislation  
Besides being the biggest change to PV pertaining to human interest, 
the new legislation has some following challenges [25]: 
• Inconsistent requirement across member states, for e.g. the 
reporting requirements for ICSRs are revised thrice since July-2012.  
• Significant implications for ability to monitor & maintain 
compliance, inconsistency with legislation with respect to no 
additional requirements unless for PV reasons. 
• Submission of non-serious cases to Eudravigilance. 
• Delay in transposition of directive in most member States, 
inconsistencies in adoption and rejections of requests in line with 
Directive and inconsistencies between finalized modules. 
• Lack of harmonization with developing countries. 
• Ad hoc requests for spontaneous data reviews that are not 
consistent with new principles, format and content: 
– requests to continue cumulative /interval reviews of spontaneous 
data, even they have proved to be negative on many previous 
occasions 
– provision of line listings of case reports with a fatal outcome 
• Reporting of ADRs to be done in a structured manner and to the 
highest possible quality standards to support accurate detection and 
analysis of drug safety signals. 
• Specific guidance is required on how to handle “invalid reports” 
and reports identified through social networking websites, web 
blogs and other such sources of data. 
Achievements of new eu pv legislation 
After implementation of this legislation from July 2012, a huge change 
has been delivered for better public health improvement [26]. 
• Better public participation 
– increase of patient reports by 10,000 
– Patients and HCPs voting on PRAC 
• Better planning: RMPs are now routinely submitted 
• Better evidence: routine identification of data needs for referrals 
• Faster decision-making 
– PRAC referrals are now finalized in 1 to 8 months 
– PSURs/PBRERs directly result in label changes 
• Greater transparency: agendas, minutes, signals of PRAC meetings 
• Better information: black triangle, ADR reporting, warnings in 
SmPCs/PILs 
CONCLUSION 
This EU PV legislation represents the most extensive change to the 
EU PV requirements for over a decade and biggest changes to human 
medicines since the establishment of EMA in 1995. As a result, there 
is a major impact on earlier regulatory processes and numerous new 
processes replaced the older ones.  
In addition, the current sets of USFDA and EMA guidance are driven 
by similar objectives for identification, monitoring and minimization 
of risk to patient safety. As a result, they frequently lead to the 
generation of similar data needs. In today’s global market 
environment such similar data requirements facilitate the exchange 
of information between the regulators. The central concept for both 
agencies is assessing risk and determining if it is acceptable. Both 
USFDA REMS and EMA RMPs currently provide comparable 
comprehensive post approval guidance for the identification, 
monitoring and minimization of risk to patient safety with some 
differences in respective implementation toolkits [24].  
The PV system in India is still not well developed. Despite of recent 
implementation of a well structured PVPI in accordance with the 
objectives and recommendations of WHO by CDSCO, desired success 
is still a distant dream. However, the reporting rate of ADRs is 
increasing as compared to previous programmes. The NCC is making 
efforts to enhance the visibility of PVPI by regularly publishing the 
PVPI Newsletters and distributing them within India and overseas 
[27]. 
The new EU PV Legislation has resulted in major implications on 
human resources in the field of PV, information technology and 
regulatory in addition to financial resources. The MAHs have played 
a crucial role to re-engineer processes and databases, revise 
procedures, and train staff etc. after implementation of the 
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legislation from July 2012. The work of the EU regulatory network is 
intensifying and the changes from new legislation are significant. 
The EU regulators are working with industry and patient and 
healthcare groups to deliver better public health protection through 
better PV. “The full implementation of new EU PV Legislation is 
estimated to save between 591 and 5910 lives, while providing 
savings to society of some €2.5 billion per year across the EU” [28]. 
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